Drug

E-7090 clinical trials

Also written E7090.

studies test it: 7
open now: 2
in phase 3: 0
first study started: 2014

How each study uses E-7090 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the E-7090 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

E7090: 6

Other names

Tasurgratinib: 1

Studies by the year they started

7 studies that test it; most in 2020 (5)

Studies that test E-7090, by start year
Year	Studies
2014	1
2020	5
2021	1

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Neoplasms: 1
Breast Neoplasms: 1
Cholangiocarcinoma: 1

Who runs them

Industry 6 · Other 1

Eisai Co., Ltd. (5) · Eisai Limited (1) · National Cancer Center, Japan (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source
One of Tyrosine kinase inhibitors (TKIs) source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test E-7090.

Aug 2027Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy ParticipantsPhase 1 · Eisai Co., Ltd.

Studies

Open first, then newest update. How each study uses E-7090 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Codes

What other systems call E-7090 · ClinicalTrials.gg INT018034

UNII (FDA) TN7CUD1NGATASURGRATINIBConfirmed FDA, Wikidata
Wikidata Q27896113E-7090Confirmed FDA, Wikidata
DrugBank DB21222One source Wikidata

System	Code	Name there	Checked by
UNII (FDA)	TN7CUD1NGA	TASURGRATINIB	Confirmed FDA, Wikidata
Wikidata	Q27896113	E-7090	Confirmed FDA, Wikidata
DrugBank	DB21222	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.